Dr. Benjamin Ungar, MD
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Icahn School of Medicine at Mount Sinai (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 289
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: Icahn School of Medicine at Mount Sinai
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
NY license 309485
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 289
- Services billed
- 2,345
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Test for allergy using skin patch | 1,126 | 16 |
| Established patient office or other outpatient visit, 30-39 minutes | 123 | 77 |
| Established patient office or other outpatient visit, 20-29 minutes | 94 | 69 |
| Therapy procedure using ultraviolet radiation with tar or petroleum jelly application | 69 | 26 |
| Injection of drug or substance under skin or into muscle | 48 | 23 |
| Telephone medical discussion with physician, 11-20 minutes | 39 | 36 |
| Treatment of inflammatory skin disease using laser, less than 250.0 sq cm | 34 | 12 |
| New patient office or other outpatient visit, 45-59 minutes | 33 | 33 |
| New patient office or other outpatient visit, 30-44 minutes | 16 | 16 |
| Destruction of precancer skin growth, 1 growth | 14 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clobetasol Propionate Other prescribers in New York, NY | 172 |
| Minoxidil Other prescribers in New York, NY | 167 |
| Ketoconazole Other prescribers in New York, NY | 77 |
| Tacrolimus Other prescribers in New York, NY | 57 |
| Dupixent Pen (dupilumab) Other prescribers in New York, NY | 47 |
| Triamcinolone Acetonide Other prescribers in New York, NY | 36 |
| Hydrocortisone Other prescribers in New York, NY | 28 |
| Dupixent Syringe (dupilumab) Other prescribers in New York, NY | 26 |
| Doxycycline Hyclate Other prescribers in New York, NY | 22 |
| Tretinoin | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 234 payments worth $86,788 in total to this clinician.
| Eli Lilly and Company | $23,652 |
|---|---|
| Galderma Laboratories, L.P. | $15,120 |
| AbbVie Inc. | $11,950 |
| Sun Pharmaceutical Industries Inc. | $10,317 |
| Pfizer Inc. | $7,309 |
| Leo Pharma Inc. | $6,237 |
| Lilly USA, LLC | $3,353 |
| Janssen Scientific Affairs, LLC | $3,053 |
| Consulting Fee | $70,566 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $8,182 |
| Food and Beverage | $5,029 |
| Travel and Lodging | $3,011 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Dec 17, 2025 | Consulting Fee OLUMIANT · Immunology | $8,000 |
| Sun Pharmaceutical Industries Inc. Jun 28, 2025 | Consulting Fee Leqselvi · Dermatology | $5,000 |
| Galderma Laboratories, L.P. Jul 26, 2025 | Consulting Fee NEMLUVIO · DERMATITIS | $4,830 |
| Pfizer Inc. Nov 10, 2025 | Consulting Fee LITFULO · IMMUNOLOGY | $4,580 |
| AbbVie Inc. Nov 6, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $3,900 |
| Eli Lilly and Company Aug 20, 2025 | Compensation for services other than consulting (speaking, faculty) OLUMIANT · Immunology | $3,200 |
| Sun Pharmaceutical Industries Inc. Oct 11, 2025 | Consulting Fee Leqselvi · Dermatology | $3,000 |
| Galderma Laboratories, L.P. Jul 3, 2025 | Consulting Fee | $2,939 |
| Galderma Laboratories, L.P. Jul 3, 2025 | Consulting Fee | $2,939 |
| Eli Lilly and Company Aug 20, 2025 | Compensation for services other than consulting (speaking, faculty) OLUMIANT · Immunology | $2,800 |
All 50 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Sun Pharmaceutical Industries Inc. Dec 19, 2025 | Consulting Fee Leqselvi · Dermatology | $720 |
| Janssen Scientific Affairs, LLC Dec 19, 2025 | Consulting Fee | $605 |
| Leo Pharma Inc. Dec 18, 2025 | Consulting Fee ADBRY; ANZUPGO · DERMATOLOGY | $1,850 |
| Eli Lilly and Company Dec 17, 2025 | Consulting Fee OLUMIANT · Immunology | $8,000 |
| Eli Lilly and Company Dec 17, 2025 | Consulting Fee OLUMIANT · Immunology | $2,800 |
| Lilly USA, LLC Dec 15, 2025 | Consulting Fee EBGLYSS · Immunology | $2,400 |
| Arcutis Biotherapeutics, Inc. Dec 14, 2025 | Consulting Fee Zoryve · Dermatology | $550 |
| Galderma Laboratories, L.P. Dec 8, 2025 | Consulting FeeCompany’s descriptionGalderma Nemolizumab PN-AN Steering Committee | $2,070 |
| Janssen Scientific Affairs, LLC Dec 5, 2025 | Consulting Fee | $303 |
| Eli Lilly and Company Nov 22, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $379 |
| Eli Lilly and Company Nov 22, 2025 | Travel and Lodging travel to CHICAGO, NY · in-kind | $158 |
| Eli Lilly and Company Nov 22, 2025 | Travel and Lodging travel to CHICAGO, NY · in-kind | $136 |
| AbbVie Inc. Nov 11, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $650 |
| Pfizer Inc. Nov 10, 2025 | Consulting Fee LITFULO · IMMUNOLOGY | $4,580 |
| AbbVie Inc. Nov 6, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $3,900 |
| Leo Pharma Inc. Nov 6, 2025 | Consulting Fee ANZUPGO; SPEVIGO; ADBRY · DERMATOLOGY | $2,220 |
| AbbVie Inc. Nov 6, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $1,625 |
| AbbVie Inc. Nov 6, 2025 | Travel and Lodging RINVOQ · IMMUNOLOGY · travel to NEW YORK, NY · in-kind | $131 |
| Janssen Scientific Affairs, LLC Oct 20, 2025 | Consulting Fee TREMFYA · Immunology | $2,118 |
| Sun Pharmaceutical Industries Inc. Oct 11, 2025 | Consulting Fee Leqselvi · Dermatology | $3,000 |
| Sun Pharmaceutical Industries Inc. Oct 11, 2025 | Travel and Lodging Leqselvi · Dermatology · travel to Dallas, TX · in-kind | $602 |
| Sun Pharmaceutical Industries Inc. Oct 11, 2025 | Travel and Lodging Leqselvi · Dermatology · travel to Dallas, TX · in-kind | $194 |
| Sun Pharmaceutical Industries Inc. Oct 11, 2025 | Travel and Lodging Leqselvi · Dermatology · travel to Dallas, TX | $135 |
| Eli Lilly and Company Aug 20, 2025 | Compensation for services other than consulting (speaking, faculty) OLUMIANT · Immunology | $3,200 |
| Eli Lilly and Company Aug 20, 2025 | Compensation for services other than consulting (speaking, faculty) OLUMIANT · Immunology | $2,800 |
| Eli Lilly and Company Aug 20, 2025 | Compensation for services other than consulting (speaking, faculty) OLUMIANT · Immunology | $800 |
| AbbVie Inc. Aug 18, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $650 |
| Eli Lilly and Company Aug 16, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind Company’s descriptionTRAVEL EXPENSES RELATED TO PROVIDING RESEARCH RELATED SERVICES | $385 |
| Eli Lilly and Company Aug 16, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $153 |
| Eli Lilly and Company Aug 16, 2025 | Travel and Lodging travel to CHICAGO, NY · in-kind | $153 |
| Eli Lilly and Company Aug 16, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $149 |
| Eli Lilly and Company Aug 16, 2025 | Travel and Lodging travel to CHICAGO, NY · in-kind | $136 |
| Galderma Laboratories, L.P. Jul 26, 2025 | Consulting Fee NEMLUVIO · DERMATITIS | $4,830 |
| AbbVie Inc. Jul 21, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $2,600 |
| Galderma Laboratories, L.P. Jul 3, 2025 | Consulting Fee | $2,939 |
| Galderma Laboratories, L.P. Jul 3, 2025 | Consulting Fee | $2,939 |
| Sun Pharmaceutical Industries Inc. Jun 28, 2025 | Consulting Fee Leqselvi · Dermatology | $5,000 |
| Sun Pharmaceutical Industries Inc. Jun 28, 2025 | Travel and Lodging Leqselvi · Dermatology · travel to Chicago, IL | $253 |
| Arcutis Biotherapeutics, Inc. Jun 16, 2025 | Consulting Fee Zoryve · Dermatology | $1,100 |
| AbbVie Inc. May 28, 2025 | Consulting Fee | $488 |
| Sanofi-aventis U.S. LLC May 6, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,382 |
| AbbVie Inc. Apr 21, 2025 | Consulting Fee RINVOQ · IMMUNOLOGY | $650 |
| Leo Pharma Inc. Apr 3, 2025 | Consulting Fee ANZUPGO; ADBRY · DERMATOLOGY | $1,850 |
| Lilly USA, LLC Mar 14, 2025 | Consulting Fee EBGLYSS · Immunology | $800 |
| Arcutis Biotherapeutics, Inc. Mar 12, 2025 | Consulting Fee Zoryve · Dermatology | $550 |
| Eli Lilly and Company Feb 21, 2025 | Consulting Fee OLUMIANT · Immunology | $2,000 |
| E.r. Squibb & Sons, L.l.c. Jan 27, 2025 | Travel and Lodging travel to NEW YORK, NY | $44.50 |
| Pfizer Inc. Jan 21, 2025 | Consulting Fee LITFULO · IMMUNOLOGY | $2,310 |
| Galderma Laboratories, L.P. Jan 20, 2025 | Consulting Fee | $2,070 |
| Eli Lilly and Company Jan 2, 2025 | Consulting Fee OLUMIANT · Immunology | $2,400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $744,064 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
Sanofi US Services Inc. · Terminated · NCT06444451 - A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Active, not recruiting · NCT06407934 - Characterizing the Molecular Cutaneous Phenotype of Seborrheic Dermatitis and Treatment Response to Ruxolitinib 1.5 percent Cream
Incyte Corporation - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
Sanofi US Services Inc. · Completed · NCT06224348
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.